PDCD1 and neoplasm: Indeed, the binding of PD-1 to its receptors, PD-L1 or PD-L2, which are expressed on tumor cells, leads to a reduction in T cell proliferation and the production of inflammatory cytokines, resulting in the inhibition of their ability to target cancer cells [11].